Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Evaluates Alli For Potential Serious Risk Of Kidney Stones

This article was originally published in The Tan Sheet

Executive Summary

FDA adds kidney stones to the list of potential signals of a serious risk for alli based on AER information gathered between July and October 2011. GSK, which is confident in the safety and efficacy of alli when used correctly, placed the only OTC weight-loss drug on the auction block last April, but needs a buyer.

Advertisement

Related Content

Alli Labels In U.S. Add Seizure Advisory Similar To E.U. Change
Alli Labels In U.S. Add Seizure Advisory Similar To E.U. Change
Prestige Acquires 17 Glaxo OTC Brands, Enters Analgesics Market
In Brief
In Brief
GlaxoSmithKline's OTC Garage Sale Includes alli, FiberChoice
FDA Alerts Public To Ongoing Safety Review Of Orlistat In GSK, Roche Drugs
FDA Evaluating Orlistat For Potential Serious Risks
Alli Sales Slender On Lower Retailer Demand, Flatten GSK Consumer Sales
GSK Touts Alli As Tip Of OTC Strength, Reaffirms Consumer Commitment

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS105508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel